Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction

Table 2 Comparison of inflammatory factors and immune levels between the two groups (mean ± SD)

Group		Control group (n = 41)	Observation group (n = 41)
hs-CRP (mg/L)	Before treatment	10.63 ± 2.58	10.49 ± 2.44
	After treatment	7.23 ± 1.96a	5.48 ± 1.67a,c
TNF-α (pg/mL)	Before treatment	58.69 ± 6.32	59.02 ± 7.44
	After treatment	46.58 ± 5.24a	37.02 ± 4.63a,c
HMGBl (µg/L)	Before treatment	5.84 ± 0.56	5.81 ± 0.59
	After treatment	3.23 ± 0.52a	2.94 ± 0.43a,c
PON-1 (U/L)	Before treatment	135.23 ± 25.21	130.58 ± 22.17
	After treatment	159.63 ± 25.74a	174.25 ± 31.02a,c
ESR (mm/h)	Before treatment	32.15 ± 5.27	30.96 ± 6.42
	After treatment	19.36 ± 3.78a	13.02 ± 4.11a,c
MIF (ng/mL)	Before treatment	84.96 ± 5.87	86.02 ± 8.11
	After treatment	76.36 ± 6.14a	68.21 ± 5.47a,c

^aP < 0.05 vs before treatment.

^cP < 0.05 vs the control group.

hs-CRP: High-sensitivity-C reactive protein; TNF-α: Tumor necrosis factor-alpha; HMGBl: High-mobility group protein B1; PON-1: Paraoxonase-1; ESR: Erythrocyte sedimentation rate; MIF: Macrophage migration inhibitory factor.